Polaryx Therapeutics (PLYX) Accumulated Expenses (2024 - 2026)

Polaryx Therapeutics (PLYX) has reported Accumulated Expenses for 3 consecutive years, with $45000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses changed N/A year-over-year to $45000.0; the TTM figure through Mar 2026 stood at $45000.0 (changed N/A YoY), while the FY2025 annual figure was $21000.0, down 75.86% from the prior year.
• Accumulated Expenses advanced to $45000.0 in Q1 2026 per PLYX's latest filing, from $21000.0 in the prior quarter.
• Across five years, Accumulated Expenses topped out at $87000.0 in Q4 2024 and bottomed at $21000.0 in Q4 2025.
• Historically, Accumulated Expenses has averaged $51000.0 across 3 years, with a median of $45000.0 in 2026.
• On a YoY basis, Accumulated Expenses climbed as much as 75.86% in 2025 and fell as far as 75.86% in 2025.
• Polaryx Therapeutics' Accumulated Expenses stood at $87000.0 in 2024, then plunged by 75.86% to $21000.0 in 2025, then surged by 114.29% to $45000.0 in 2026.
• Business Quant data shows PLYX's Accumulated Expenses at $45000.0 in Q1 2026, $21000.0 in Q4 2025, and $87000.0 in Q4 2024.